Project Grant R03DE034506
Award Date
7/15/25
Completion Date
7/14/27
Dollars Obligated
$320K
Federal Agency
National Institute of Dental and Craniofacial Research
Federal Grant Program
93.121
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This Project Grant award of $707,526 from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), supports research to investigate mechanisms that contribute to poor response to epidermal growth factor receptor (EGFR) inhibition therapies in head and neck squamous cell carcinoma (HNSCC) patients receiving radiotherapy. The key research objectives are to determine if interleukin-1 (IL-1)-mediated NADPH oxidase 2...
This Project Grant award of $229,440 from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), supports research to investigate the mechanisms driving differential responses to a novel radio-immunotherapy combination in preclinical models of head and neck squamous cell carcinoma (HNSCC) and pancreatic adenocarcinoma (PDAC). The research aims to elucidate how regulatory T cells mediate the divergent responses...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research (CFDA 93.121) program, provides $234,750 to Emory University from April 1, 2025 to March 31, 2027. The project aims to investigate how the inhibitor of apoptosis protein (IAP) antagonist Tolinapant can enhance the abscopal anti-tumor immune responses induced by radiotherapy (RT) in head and neck cancer models. The research will utilize innovative murine...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,295,508 to The Washington University in St. Louis to develop novel inhibitors of the NRF2 transcription factor and evaluate their ability to sensitize head and neck squamous cell carcinoma (HNSCC) to radiation therapy. The research aims to leverage two distinct NRF2 inhibitors, VVD065 and WCDD115, as synthetic combination agents with radiation therapy in human HNSCC xenografts, mouse...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $170,208 over 4 years to support research aimed at defining the mechanisms through which polyamines modulate anti-tumor immune responses in head and neck squamous cell carcinoma (HNSC). The research, led by principal investigator R. Alex Harbison, MD at Washington University, will utilize in vitro and in vivo models to...
The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $1,403,398 Project Grant under the Oral Diseases and Disorders Research program (CFDA 93.121) to The General Hospital Corporation (Massachusetts General Hospital) to conduct research on precision imaging approaches for understanding the spatial regulators of the hybrid epithelial/mesenchymal state in head and neck cancer. The project aims to utilize advanced imaging techniques to investigate how the hybrid...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $483,360 to the University of California, San Diego (UCSD) to conduct research aimed at identifying new precision therapies for oral cancer. The key focus is to exploit vulnerabilities in the EGFR/HER3/HER2 oncogenic signaling circuitry to disrupt immune evasive mechanisms and enhance the activity of anti-PD-1...
The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $317,000 project grant (CFDA No. 93.121 - Oral Diseases and Disorders Research) to Temple University to investigate the role of amplified protein kinases in head and neck squamous cell carcinoma (HNSCC) progression and therapy resistance. The 2-year project aims to test whether the protein kinase TNIK, which is amplified in 20% of HNSCC cases, sustains HNSCC cell proliferation and viability by activating focal...
The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $252,915 Project Grant under the Oral Diseases and Disorders Research program (CFDA 93.121) to Rutgers, The State University of New Jersey. The project aims to apply data science and machine learning techniques to classify aggressive tissue phenotypes and predict disease-free survival in HPV-negative head and neck squamous cell carcinoma (HNSCC). Specifically, the research will delineate molecular variations within...
This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $642,488 to a collaborative research partnership between Henry Ford Health and Michigan State University Health Sciences. The funding will support a 5-year research project focused on understanding the mechanisms by which human papillomavirus (HPV) promotes immune evasion in head and neck squamous cell carcinomas (HNSCC)....